The other line runs vertically down the middle of the front/outer surface, dividing it into front and outer sections
Eli Lilly said Thursday that its triple-agonist obesity drug retatrutide hit every primary and key secondary endpoint in TRIUMPH-1, the Phase 3 registration trial that will anchor the company's expected FDA filing
Retatrutide Activates GIP, GLP-1, and Glucagon Receptors Research suggests retatrutide functions as: A GLP-1 receptor agonist A glucagon receptor agonist A glucose-dependent insulinotropic polypeptide receptor agonist This multi-pathway receptor activity may influence: Glucose metabolism Energy expenditure Appetite signaling Glycemic control Endocrine pathways Overall metabolic regulation Retatrutide also activates GIP receptor pathways that researchers believe may contribute to improved metabolic signaling and weight management outcomes
This hormonal response helps slow gastric emptying and sends fullness signals to the brain (NIH)
By month 4, GI side effects fade into background noise for 85%+ of patients, leaving appetite suppression as the primary ongoing effect, which is the desired therapeutic response
Moreover, GIP administration reduces lipolysis-related genes expression in adipose tissue of overweight subjects and consequently decreases circulating free fatty acid levels [37]
